$90.21
+0.28 (+0.31%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-11.78%
1Y
+642.47%
YTD
-10.28%
Open$88.84
Previous Close$89.93
Day High$92.61
Day Low$87.88
52W High$151.02
52W Low$11.28
Volume—
Avg Volume1.50M
Market Cap4.28B
P/E Ratio—
EPS$-3.90
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$105.59
Below
SMA 200
$59.11
Above
RSI (14)
39.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
18 analysts
Price Target
-71.7% upside
Current
$90.21
$90.21
Target
$25.56
$25.56
$16.07
$25.56 avg
$38.64
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 856.50M | 842.65M | 828.36M |
| Net Income | -244,490,059 | -213,463,076 | -182,555,570 |
| Profit Margin | -28.6% | -25.3% | -22.0% |
| EBITDA | -292,781,484 | -259,398,727 | -297,826,578 |
| Free Cash Flow | -124,649,561 | -156,876,378 | -179,431,543 |
| Rev Growth | +6.2% | -3.6% | +12.6% |
| Debt/Equity | 1.11 | 1.11 | 1.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |